Neutralization activity and kinetics of two broad-range human monoclonal IgG1 derived from recombinant Fab fragments and directed against Hepatitis C Virus E2 glycoprotein

New Microbiologica

Volumn 35, Issue 4, 2012, Pages 475-479

  Diotti, Roberta Antonia ^a   Sautto, Giuseppe Andrea ^a   Solforosi, Laura ^a   Mancini, Nicasio ^a   Clementi, Massimo ^a   Burioni, Roberto ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

E2 glycoprotein; Hepatits C virus (HCV); Neutralizing anti HCV antibodies

Indexed keywords

GLYCOPROTEIN E2, HEPATITIS C VIRUS; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; VIRUS ENVELOPE PROTEIN;

ARTICLE; CHEMISTRY; GENETICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGY; KINETICS; SERODIAGNOSIS; VIROLOGY;

ANTIBODIES, MONOCLONAL; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; KINETICS; NEUTRALIZATION TESTS; VIRAL ENVELOPE PROTEINS;

HEPATITIS C VIRUS;

EID: 84869187965     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. ALTER M.J. (1997). The epidemiology of acute and chronic hepatitis C. Clin. Liver. Dis. 1 (3), 559-568, vi-vii.
2. BARTOSCH B., DUBUISSON J., COSSET F.L. (2003). Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197 (5), 633-642. (Pubitemid 36314658)
3. BURIONI R., BUGLI F., MANCINI N., ROSA D., DI CAMPLI C., MORONCINI G., MANZIN A., ABRIGNANI S., VARALDO P.E., CLEMENTI M., FADDA G. (2001). Non neutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs. Virology. 288 (1), 29-35. (Pubitemid 32846471)
4. BURIONI R., CANDUCCI F., MANCINI N., CLEMENTI N., SASSI M., DE MARCO D., DIOTTI R.A., SAITA D., SAMPAOLO M., SAUTTO G., PIANEZZE M., CLEMENTI M. (2010). Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV). Virology. 399 (1), 144-152.
5. BURIONI R., PEROTTI M., MANCINI N., CLEMENTI M. (2008). Perspectives for the utilization of neutralizing human monoclonal antibodies as anti-HCV drugs. J. Hepatol. 49 (2), 299-300.
6. BURIONI R., PLAISANT P., BUGLI F., DELLI CARRI V., CLEMENTI M., FADDA G. (1998a). A vector for the expression of recombinant monoclonal Fab fragments in bacteria. J. Immunol. Methods. 217 (1-2), 195-199. (Pubitemid 28449043)
7. BURIONI R., PLAISANT P., MANZIN A., ROSA D., DELLI CARRI V., BUGLI F., SOLFOROSI L., ABRIGNANI S., VARALDO P.E., FADDA G., CLEMENTI M. (1998b). Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments. Hepatology. 28 (3), 810-814. (Pubitemid 28405434)
8. CHANDRA P.K., HAZARI S., POAT B., GUNDUZ F., PRABHU R., LIU G., BURIONI R., CLEMENTI M., GARRY R.F., DASH S. (2010). Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone. Virol. J. 7, 118.
9. CLEMENTI N., DE MARCO D., MANCINI N., SOLFOROSI L., MORENO G.J., GUBAREVA L.V., MISHIN V., DI PIETRO A., VICENZI E., SICCARDI A.G., CLEMENTI M., BURIONI R. (2011). A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes. PLoS One. 6 (12), e28001.
10. CLEMENTI N., MANCINI N., SOLFOROSI L., CASTELLI M., CLEMENTI M., BURIONI R. (2012). Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens. Int. J. Mol. Sci. 13 (7), 8273-8292.
11. DE MARCO D., CLEMENTI N., MANCINI N., SOLFOROSI L., MORENO G.J., SUN X., TUMPEY T.M., GUBAREVA L.V., MISHIN V., CLEMENTI M., BURIONI R. (2012). A non-VH1-69 heterosubtypic neutralizing human monoclonal antibody protects mice against H1N1 and H5N1 viruses. PLoS One 7 (4), e34415.
12. DEUTSCH M., HADZIYANNIS S.J. (2008). Old and emerging therapies in chronic hepatitis C: an update. J. Viral. Hepat. 15 (1), 2-11. (Pubitemid 350243574)
13. FORESTIER N., REESINK H.W., WEEGINK C.J., MCNAIR L., KIEFFER T.L., CHU H.M., PURDY S., JANSEN P.L., ZEUZEM S. (2007). Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology. 46 (3), 640-648. (Pubitemid 47436108)
14. HABERSTROH A., SCHNOBER E.K., ZEISEL M.B., CAROLLA P., BARTH H., BLUM H.E., COSSET F.L., KOUTSOUDAKIS G., BARTENSCHLAGER R., UNION A., DEPLA E., OWSIANKA A., PATEL A.H., SCHUSTER C., STOLLKELLER F., DOFFOEL M., DREUX M., BAUMERT T.F. (2008). Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology. 135 (5), 1719-1728 e1.
15. JIANG X.R., SONG A., BERGELSON S., ARROLL T., PAREKH B., MAY K., CHUNG S., STROUSE R., MIRE-SLUIS A., SCHENERMAN M. (2011). Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat. Rev. Drug. Discov. 10 (2), 101-111.
16. JOHANSSON D., VOISSET C., TARR A.W., AUNG M., BALL J.K., DUBUISSON J., PERSSON M.A. (2007). Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc. Natl. Acad. Sci USA. 104 (41), 16269-16274. (Pubitemid 350099395)
17. LESNIEWSKI R., OKASINSKI G., CARRICK R., VAN SANT C., DESAI S., JOHNSON R., SCHEFFEL J., MOORE B., MUSHAHWAR I. (1995). Antibody to hepatitis C virus second envelope (HCV-E2) glycoprotein: a new marker of HCV infection closely associated with viremia. J. Med. Virol. 45 (4), 415-422.
18. MANCINI N., CARLETTI S., PEROTTI M., CANDUCCI F., MAMMARELLA M., SAMPAOLO M., BURIONI R. (2004). Phage display for the production of human monoclonal antibodies against human pathogens. New Microbiol. 27 (4), 315-328. (Pubitemid 40103459)
19. MANCINI N., DIOTTI R.A., PEROTTI M., SAUTTO G., CLEMENTI N., NITTI G., PATEL A.H., BALL J.K., CLEMENTI M., BURIONI R. (2009). Hepatitis C virus (HCV) infection may elicit neutralizing antibodies targeting epitopes conserved in all viral genotypes. PLoS One. 4 (12), e8254.
20. MANCINI N., SOLFOROSI L., CLEMENTI N., DE MARCO D., CLEMENTI M., BURIONI R. (2011). A potential role for monoclonal antibodies in prophylactic and therapeutic treatment of influenza. Antiviral. Res. 92 (1), 15-26.
21. MIRA J.A., GUTIERREZ-VALENCIA A., GIL IDE L., MERINO D., RIVERO A., RIOS-VILLEGAS M.J., DELGADO M., GONZALEZ-SERRANO M., COLLADO A., TORRES-TORTOSA M., OMAR M., LOPEZ-RUZ M.A., MACIAS J., ARPONEN S., PINEDA J.A. (2009). Efficacy and safety of pegy-lated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. Clin. Infect. Dis. 49 (8), e84-91.
22. PEROTTI M., GHIDOLI N., ALTARA R., DIOTTI R.A., CLEMENTI N., DE MARCO D., SASSI M., CLEMENTI M., BURIONI R., MANCINI N. (2008a). Hepatitis C virus (HCV)-driven stimulation of subfamily-restricted natural IgM antibodies in mixed cryoglobulinemia. Autoimmun. Rev. 7 (6), 468-472.
23. PEROTTI M., MANCINI N., DIOTTI R.A., TARR A.W., BALL J.K., OWSIANKA A., ADAIR R., PATEL A.H., CLEMENTI M., AND BURIONI R. (2008b). Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J. Virol. 82 (2), 1047-1052.
24. PESTKA J.M., ZEISEL M.B., BLASER E., SCHURMANN P., BARTOSCH B., COSSET F.L., PATEL A.H., MEISEL H., BAUMERT J., VIAZOV S., RISPETER K., BLUM H.E., ROGGENDORF M., BAUMERT T.F. (2007). Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl. Acad. Sci. USA. 104 (14), 6025-6030. (Pubitemid 47175652)
25. SAUTTO G., MANCINI N., DIOTTI R.A., SOLFOROSI L., CLEMENTI M., BURIONI R. (2012a). Anti-hepatitis C virus E2 (HCV/E2) glycoprotein monoclonal antibodies and neutralization interference. Antiviral. Res. 96 (1), 82-89.
26. SAUTTO G., MANCINI N., SOLFOROSI L., DIOTTI R.A., CLEMENTI M., BURIONI R. (2012b). HCV proteins and immunoglobulin variable gene (IgV) subfamilies in HCV-induced type II mixed cryoglobulinemia: a concurrent pathogenetic role. Clin. Dev. Immunol. 2012, 705013.
27. SEEFF L.B., BUSKELL-BALES Z., WRIGHT E.C., DURAKO S.J., ALTER H.J., IBER F.L., HOLLINGER F.B., GITNICK G., KNODELL R.G., PERRILLO R.P., ET AL. (1992). Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N. Engl. J. Med. 327 (27), 1906-1911. (Pubitemid 23006965)
28. SOLFOROSI L., MANCINI N., CANDUCCI F., CLEMENTI N., SAUTTO G.A., DIOTTI R.A., CLEMENTI M., BURIONI R. (2012). A phage display vector optimized for the generation of human antibody combinatorial libraries and the molecular cloning of monoclonal antibody fragments. New Microbiol. 35 (3), 289-294.
29. TARR A.W., URBANOWICZ R.A., JAYARAJ D., BROWN R.J., MCKEATING J.A., IRVING W.L., BALL J.K. (2012). Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J. Virol. 86 (5), 2739-2749.
30. TONG C.Y., GILMORE I.T., HART C.A. (1995). HCV-associated liver cancer. Lancet. 345 (8956), 1058-1059.
31. WAKITA T., PIETSCHMANN T., KATO T., DATE T., MIYAMOTO M., ZHAO Z., MURTHY K., HABERMANN A., KRAUSSLICH H.G., MIZOKAMI M., BARTENSCHLAGER R., LIANG T.J. (2005). Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11 (7), 791-796. (Pubitemid 41021213)
32. YU M.Y., BARTOSCH B., ZHANG P., GUO Z. P., RENZI P.M., SHEN L.M., GRANIER C., FEINSTONE S.M., COSSET F.L., PURCELL R.H. (2004). Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc. Natl. Acad. Sci USA. 101 (20), 7705-7710. (Pubitemid 38658093)
33. ZHANG P., ZHONG L., STRUBLE E.B., WATANABE H., KACHKO A., MIHALIK K., VIRATA-THEIMER M.L., ALTER H.J., FEINSTONE S., MAJOR M. (2009). Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc. Natl. Acad. Sci. USA. 106 (18), 7537-7541.
34. ZHOU Y., BARTELS D.J., HANZELKA B.L., MUH U., WEI Y., CHU H.M., TIGGES A.M., BRENNAN D.L., RAO B.G., SWENSON L., KWONG A.D., LIN C. (2008). Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrob. Agents Chemother. 52 (1), 110-120.